Literature DB >> 24418062

Increased risk of preterm delivery and pre-eclampsia in women with polycystic ovary syndrome and hyperandrogenaemia.

K V Naver1, J Grinsted, S O Larsen, P L Hedley, F S Jørgensen, M Christiansen, L Nilas.   

Abstract

OBJECTIVE: To study the risk of adverse pregnancy outcomes in women with polycystic ovary syndrome (PCOS), and to examine the role of hyperandrogenaemia.
DESIGN: Cohort study.
SETTING: Singleton pregnancies in women with PCOS identified at a private fertility clinic during 1997-2010 and a background population including all singleton deliveries at Hvidovre Hospital, Denmark, in 2005. POPULATION: A cohort of 459 women with PCOS and a background population of 5409 women.
METHODS: Obstetric outcomes were extracted from national Danish registries and odds ratios (ORs) were calculated by multiple logistic regression analysis, adjusting for age, parity, and body mass index. MAIN OUTCOME MEASURES: Risk of pre-eclampsia, preterm delivery, and small for gestational age offspring in the entire PCOS population and in a subsample with hyperandrogenaemia.
RESULTS: Women with PCOS had an increased risk of preterm delivery <37 weeks of gestation (OR 2.28; 95% confidence interval, 95% CI, 1.51-3.45; P < 0.0001). The elevated risk was confined to hyperandrogenic women with PCOS: preterm delivery before 37 weeks of gestation (OR 2.78; 95% CI 1.62-4.77; P < 0.0001), and was not seen in normoandrogenic women with PCOS (OR 1.35; 95% CI 0.54-3.39; P = 0.52). The overall risk of pre-eclampsia was not elevated (OR 1.69; 95% CI 0.99-2.88; P = 0.05) compared with the background population, but was significantly increased in the hyperandrogenic subsample (OR 2.41; 95% CI 1.26-4.58; P < 0.001). The risk of small for gestational age offspring was similar in all groups.
CONCLUSION: Women with PCOS had an increased risk of preterm delivery compared with the background population. The increased risk was confined to hyperandrogenic women with PCOS who had a two-fold increased risk of preterm delivery and pre-eclampsia.
© 2014 Royal College of Obstetricians and Gynaecologists.

Entities:  

Keywords:  Hyperandrogenaemia; polycystic ovary syndrome; pre-eclampsia; preterm delivery

Mesh:

Year:  2014        PMID: 24418062     DOI: 10.1111/1471-0528.12558

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  30 in total

1.  Gestational exposure to elevated testosterone levels induces hypertension via heightened vascular angiotensin II type 1 receptor signaling in rats.

Authors:  Vijayakumar Chinnathambi; Amar S More; Gary D Hankins; Chandra Yallampalli; Kunju Sathishkumar
Journal:  Biol Reprod       Date:  2014-05-22       Impact factor: 4.285

Review 2.  Polycystic ovary syndrome throughout a woman's life.

Authors:  José Bellver; Luis Rodríguez-Tabernero; Ana Robles; Elkin Muñoz; Francisca Martínez; José Landeras; Juan García-Velasco; Juan Fontes; Mónica Álvarez; Claudio Álvarez; Belén Acevedo
Journal:  J Assist Reprod Genet       Date:  2017-09-27       Impact factor: 3.412

Review 3.  Targets to treat metabolic syndrome in polycystic ovary syndrome.

Authors:  Shruthi Mahalingaiah; Evanthia Diamanti-Kandarakis
Journal:  Expert Opin Ther Targets       Date:  2015-10-21       Impact factor: 6.902

4.  Endometrial stromal fibroblasts from women with polycystic ovary syndrome have impaired progesterone-mediated decidualization, aberrant cytokine profiles and promote enhanced immune cell migration in vitro.

Authors:  T T Piltonen; J C Chen; M Khatun; M Kangasniemi; A Liakka; T Spitzer; N Tran; H Huddleston; J C Irwin; L C Giudice
Journal:  Hum Reprod       Date:  2015-03-06       Impact factor: 6.918

Review 5.  A Narrative Review of Placental Contribution to Adverse Pregnancy Outcomes in Women With Polycystic Ovary Syndrome.

Authors:  Angela S Kelley; Yolanda R Smith; Vasantha Padmanabhan
Journal:  J Clin Endocrinol Metab       Date:  2019-11-01       Impact factor: 5.958

6.  Impact of metabolic disorders on endometrial receptivity in patients with polycystic ovary syndrome.

Authors:  Can Wang; Yang-Xing Wen; Qing-Yun Mai
Journal:  Exp Ther Med       Date:  2022-01-14       Impact factor: 2.447

Review 7.  Polycystic ovary syndrome as a paradigm for prehypertension, prediabetes, and preobesity.

Authors:  Manuel Luque-Ramírez; Héctor F Escobar-Morreale
Journal:  Curr Hypertens Rep       Date:  2014-12       Impact factor: 5.369

Review 8.  Inflammation and reproductive function in women with polycystic ovary syndrome†.

Authors:  Leandro M Velez; Marcus Seldin; Alicia B Motta
Journal:  Biol Reprod       Date:  2021-06-04       Impact factor: 4.285

9.  Polycystic Ovary Syndrome and the Forgotten Uterus.

Authors:  Pardis Hosseinzadeh; Maya Barsky; William E Gibbons; Chellakkan S Blesson
Journal:  F S Rev       Date:  2020-12-13

Review 10.  A Narrative Review of Current Understanding of the Pathophysiology of Polycystic Ovary Syndrome: Focus on Plausible Relevance of Vitamin D.

Authors:  Rajeshwari Kalyanaraman; Lubna Pal
Journal:  Int J Mol Sci       Date:  2021-05-05       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.